Prognostic value of modified systemic inflammatory score in patients with newly diagnosed high-grade gliomas

Abstract

Background: We aimed to build a modified systemic inflammatory score(mSIS) based on preoperative albumin, fibrinogen, lactate dehydrogenase, and neutrophil-lymphocyte ratio in patients with high-grade glioma.

Material and methods: Data of 318 patients with high-grade gliomas were retrospectively analyzed. The SIS was developed and its associations with clinicopathological features and overall survival (OS) were evaluated.

Results: The mSIS consisted of serum albumin, fibrinogen, lactate dehydrogenase and neutrophil-lymphocyte ratio. A high mSIS was significantly associated with age(p < 0.001), sex(p = 0.048), lymphocyte-monocyte ratio (LMR)(p = 0.025), C-reactive protein(p < 0.001), tumor grade(p = 0.006) and served as an independent prognostic factor of reduced overall survival and progression-free survival (PFS). Subgroup analysis showed that the mSIS could significantly stratify patient prognosis in different tumor grades and adjuvant therapies.

Conclusions: mSIS may predict survival and disease regression in high-grade glioma patients undergoing surgery. Management of HGG patients may need consideration of host inflammatory status.

Keywords: Glioblastoma; Glioma; Inflammatory score; Prognosis; Survival analysis.